cAMPfield launched with a $180M Series A for an oral IBD therapy.
cAMPfield is a clinical-stage biopharmaceutical company focused on developing well-tolerated and highly effective oral medicines for inflammatory diseases, particularly inflammatory bowel disease (IBD)
cAMPfield is a clinical-stage biopharmaceutical company focused on developing well-tolerated and highly effective oral medicines for inflammatory diseases, particularly inflammatory bowel disease (IBD).